{"filing":{"accession_number":"0001493152-26-034136","cik":"0001290877","ticker":null,"company_name":"Clinuvel Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1290877/000149315226034136/form6-k.htm"},"events":[{"id":19279,"run_id":17343,"accession_number":"0001493152-26-034136","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.25,"summary":"This exhibit announces CLINUVEL's commencement of trading on Nasdaq under ticker CUVL, with its existing over-the-counter ADR (CLVLY) upgrading from Level I to Level II. While the announcement describes a positive listing development, the risk statement explicitly notes \"No final decision has been made\" and \"There is no guarantee that the uplisting will proceed.\" However, the primary substance is a successful listing event rather than a delisting risk, making this classification uncertain.","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":18328,"accession_number":"0001493152-26-034136","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.25,"reasoning":"This exhibit announces CLINUVEL's commencement of trading on Nasdaq under ticker CUVL, with its existing over-the-counter ADR (CLVLY) upgrading from Level I to Level II. While the announcement describes a positive listing development, the risk statement explicitly notes \"No final decision has been made\" and \"There is no guarantee that the uplisting will proceed.\" However, the primary substance is a successful listing event rather than a delisting risk, making this classification uncertain.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:05:55.444064+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18328,"accession_number":"0001493152-26-034136","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.25,"reasoning":"This exhibit announces CLINUVEL's commencement of trading on Nasdaq under ticker CUVL, with its existing over-the-counter ADR (CLVLY) upgrading from Level I to Level II. While the announcement describes a positive listing development, the risk statement explicitly notes \"No final decision has been made\" and \"There is no guarantee that the uplisting will proceed.\" However, the primary substance is a successful listing event rather than a delisting risk, making this classification uncertain.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:05:55.444064+00:00","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-07-21"}]}